Proactive Investors - Run By Investors For Investors

Dechra Pharmaceuticals makes bolt-on acquisition

It is paying £4.4mln or 2.4-times revenues for Caledonian Holdings
Dechra Pharmaceuticals makes bolt-on acquisition
The UK group is buying a New Zealand supplier to vets specialising in horses

Dechra Pharmaceuticals PLC (LON:DPH) has made a small bolt-on acquisition.

It is paying £4.4mln or 2.4-times revenues, for Caledonian Holdings, a New Zealand supplier to vets specialising in horses.

The deal will establish Dechra as a leading equine pharmaceutical supplier in both Australia and New Zealand, the company said.

"We are pleased to have acquired the trade and assets of Caledonian which will be integrated into our existing Australian and New Zealand businesses. This will enable Dechra to leverage its position in the ANZ equine market," said chief executive Ian Page.

 

View full DPH profile View Profile

Dechra Pharmaceutical Timeline

Related Articles

Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use